I've always wondered what would happen if a drugmaker developed a drug and nobody noticed -- or cared.
I think I just found out.
On Thursday morning, MannKind
After Exubera -- Nektar Therapeutics
The more immediate question is whether Afresa will even make it to the market -- the drug does have to get past the Food and Drug Administration, after all. I don't think that MannKind has to worry about data about its effectiveness, but the safety-conscious FDA could send it back to the drawing board after it submits its marketing application early next year. There was a higher incidence of lung cancer in patients treated with Exubera versus the control group in a long-term safety analysis and, while MannKind hasn't seen any kind of signal of the same, it's usually easier to prove that something exists than that it doesn't.
With a market cap of $300 million, the risk/reward on MannKind, a Motley Fool Hidden Gems Pay Dirt pick, is looking just about right to me. The company could double from here should it gain marketing approval, and then double or triple again if the drug tops the paltry sales that Pfizer managed with Exubera. That's a lot of reward, but the unpredictable FDA introduces a lot of risk into the equation as well. If you're going to invest, buy carefully on the dips.
More Foolishness on small caps:
Find out why big returns often come in little packages by grabbing a 30-day free trial to Motley Fool Hidden Gems, our small-cap stock recommendation service.
More from The Motley Fool
Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February
MannKind's reverse stock split gave investors the blues.
Why MannKind Corporation Stock Is Sinking Today
The biopharma's reverse split isn't a hit with investors.
3 Stocks to Avoid in Biotech
Biotech stocks are known for their high growth, but they can also be toxic for your portfolio if you don't invest wisely.